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Background: It is estimated that 2.1 million individuals worldwide became newly infected with HIV in 2013, and this 
included 240,000 children (<15 years).  Most of these children live in sub-Saharan Africa and were infected by their 
HIV-positive mothers during pregnancy, childbirth or breastfeeding.   
Objective: This study sought to ascertain the different PMTCT approaches or regimens that mothers and infants 
receive, their Mother-To-Child Transmission of HIV (MTCT) rates and associated correlates in Western Kenya.  
Methods: A retrospective cohort study using prospectively collected data in Ministry of Health HIV-Exposed Infant 
(HEI) register from 24 health facilities.  The study population was HIV-positive mothers enrolled from January 2012 
to June 2013. The main outcomes were infant HIV status at 6 weeks, 9 to <18 months and 18-24 months. The 
correlates were maternal haemoglobin levels, WHO staging, CD4 counts, duration between enrolment and delivery, 
duration between enrolment and ART initiation, TB status, place of delivery, mode of delivery, and infant feeding 
options at 6 weeks, 9 to <18 months and 18-24 months. Proportions were analyzed using Chi-square tests while 
associations between MTCT correlates and outcomes were established using logistic regression.  
Results: 1,751 HIV mother-baby pairs were enrolled in the 24 health facilities: 78.1% received Highly Active 
Antiretroviral Therapy (HAART), 14.2% received Zidovudine (AZT), 1.7% received Single-dose Nevirapine (SdNVP), 
and 4.3% received no prophylaxis. MTCT rates were 5.5%, 7.4% and 5.6% at 6 weeks, 9 to <18 months and 18-24 
months, respectively. MTCT rate at 18-24 months showed a significant difference (p<0.001) across PMTCT regimens. 
Women with CD4 cells between 350 to 500 cells/mm3 were about twice as likely to have HIV-negative babies 
compared to those with CD4 cells count <350cells/mm3. Women on TB treatment are less likely to have HIV-negative 
babies compared to those without TB. Exclusive breastfeeding at 6 weeks was associated with lower MTCT rates.  
Feeding option at 6 weeks is a strong predictor of HIV status (p<0.001) as compared to babies on exclusive 
breastfeeding (EBF).  
Conclusion: Most of the mother-baby pairs received HAART. AZT depicted the lowest MTCT rate at 18-24 months.  
Higher CD4 counts, no TB signs, and EBF at 6 weeks were associated with lower MTCT rates at 18-24 months 
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1. Introduction 
The HIV/AIDS remains one of the key challenges in the 
21st century with political, economic, public health, 
social and scientific consequences globally.  HIV/AIDS 
cases have been reported in all regions of the world, but 
most people living with the disease reside in low- and 
middle-income countries, more so in sub-Sahara Africa 
that carries 60% of the world’s disease burden despite 
having only 10% of the world’s population(UNAIDS, 
2009).  
For the first time since the 1990s, the number of new 
HIV infections among children in the 21 Global Plan 
priority countries in sub-Saharan Africa dropped to 
under 200,000.  This represents a 43% decline in the 
number of new HIV infections among children in these 
21 countries since 2009, and providing reasons for 
optimism as the Global Plan pushes towards its 2015 
goals of 90% reduction.  However, between 2012 and 
2013, the pace of progress in reducing new HIV 
infections among children across the priority countries 
slowed substantially. While a number of countries made 
impressive gains, others stagnated or lost ground 
(UNAIDS, 2014).  Globally, 35 million people were living 
with HIV at the end of 2013 (WHO, 2014a).  Of these, 3.2 
million were children (<15 years old). According to 
WHO, an estimated 2.1 million individuals worldwide 
became newly infected with HIV in 2013, including over 
240,000 children (<15 years).  Most of these children 
live in sub-Saharan Africa and were infected by their 
HIV-positive mothers during pregnancy, childbirth or 
breastfeeding (WHO, 2014b).  There are 13 high burden 
countries which account for 75% of the estimated 1.5 
million pregnant women living with HIV in 2007 in low- 
and middle-income countries and nearly 75% of all 
children living with HIV. All but one of these countries 
(India) are in sub-Saharan Africa, Kenya inclusive 
(UNAIDS, 2010).  
Mother-to-child transmission (MTCT) occurs when an 
HIV-infected woman passes the virus to her baby at 
childbirth and through breastfeeding.  Almost all 
infections in infants can be avoided by timely delivery of 
known, effective interventions to prevent mother-to-
child transmission.  About 90% of these MTCT 
infections occurred in Africa where AIDS is beginning to 
reverse decades of steady progress in child survival 
(UNAIDS, 2010), as access to services for preventing the 
MTCT of HIV has increased (UNAIDS, 2010).  
Kenya’s Ministry of Health (MoH), through National 
AIDS and STI Control Program (NASCOP), took several 
actions to expand and strengthen PMTCT interventions 
in the country over the years.  In 1994, PMTCT services 
were initiated with establishment of pilot PMTCT sites 
in Nairobi, Karatina and Homa Bay.  In 1996, the Kenya 
Obstetrical and Gynecological Society (KOGS) 
spearheaded the development of the first guidelines for 
PMTCT in the country.  In 2000, a National Technical 
Working Group (TWG) on PMTCT was formed.  The 
TWG, co-chaired by NASCOP and the Division of 
Reproductive Health, coordinates implementation and 
provides technical support to the National PMTCT 
Programme. By 2002, National guidelines for PMTCT 
had been prepared and distributed (MOH, 2004).  As 
new PMTCT projects began, the TWG served as a forum 
to provide on-going review of guidelines, program 
implementation, update stakeholders and discuss 
challenges and upcoming activities.  The TWG is also 
responsible for updating national guidelines for PMTCT.  
The goal of the National PMTCT Program is in line with 
the goal set out at the United Nations General Assembly 
Special Session on HIV/AIDS (UNGASS) in 2001 to 
reduce the proportion of infants infected with HIV by 
20% by the year 2005 and 50% by 2010.  This massive 
roll out of PMTCT services aims to meet the UNGASS 
target (DOC, 2001).  In order to meet the stated PMTCT 
goals, the Kenya Ministry of Health adopted the global 
guidelines for prevention of MTCT transmission of HIV 
(MOH, 2005). In the wealthy countries, the rate of MTCT 
is less than 2% because of widespread access to anti-
retroviral therapy (ART), planned caesarean sections 
(CS), the means to safe formula feed, and access to 
quality medical services (MOH, 2008). Consequently, 
modifications on the guidelines have been made to keep 
abreast as science reveals better ways of preventing 
MTCT of HIV.  The revised 2008 PMTCT guidelines are 
part of the implementation instruments towards 
universal access to PMTCT services, and a response to 
the call to action towards HIV-free and AIDS-free 
generation (MOH, 2008). 
Prevention of Mother-to-child Transmission of HIV 
(PMTCT) services in Western Kenya started in 2000 
with the Provincial hospital being one of the original 
five PMCT pilot sites in the country.  It has shown a 
steady growth from five PMTCT sites in 2003 to the 
current 271 PMTCT sites by 2013.  This represents 88% 
(271/308) of the health facilities offering ANC services 
in Western Kenya.  For the last four years, there have 
been concerted efforts within the Counties to increase 
access to the use of the more efficacious regimens as 
provided for in the national PMTCT guidelines. In the 
current study, the different PMTCT approaches or 
regimens that mothers and infants receive, their 
correlates and MTCT rates in Western Kenya were 
determined. 
2. Methodology 
2.1 Study design 
This was a retrospective cohort study using 
prospectively collected data from 24 sampled health 
facilities providing PMTCT services according to the 
Ministry of Health/NASCOP guidelines in Vihiga, 
Kakamega, Bungoma and Busia Counties (formerly 
Western Province).  
2.2 Study population 
The study population was HIV-positive pregnant 
women who received PMTCT services during the study 
period (January 2012 to June 2013) and their HIV-
exposed infants/babies who were at least 18-24 months 
of age from the 24 sampled health facilities.   
2.3 Sampling and sample size 
Multi-stage sampling technique was adopted for the 
health facilities. Stage one involved stratifying the 
health facilities by county (Vihiga, Bungoma, Busia and 
Kakamega counties).  Stage two involved categorizing 
the health facilities by levels (county hospitals, sub-
county hospitals, health centres and dispensaries).  The 
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county hospitals that met the eligibility criteria were 
purposively sampled based on their big catchment 
areas and referral hospital status. Sub-county, health 
centres and dispensaries were randomly sampled.  Due 
to missing data, all HIV-positive mother-baby pairs data 
from the sampled health facilities were extracted from 
the period covering January 2012 to June 2013 
resulting in a total of 1751 mother-baby pairs.  The 
MOH HEI registers were the primary data collection 
tool, and missing variables from the registers 
corroborated with data from the patient files in 
Maternal and Child Health (MCH) and Comprehensive 
Care Clinics (CCCs).     
2.4 Eligibility criteria 
The inclusion criteria was a) health facilities providing 
PMTCT and Early Infant Diagnosis as per the MOH 
protocol and guidelines b) health facilities who were 
willing to give informed consent to participate in the 
study c) health facilities that started providing PMTCT 
services from January 2012 d) mother-baby pairs that 
were enrolled in the sampled health facilities between 
January 2012 to June 2013.  
2.5 Maternal and infant variables 
Maternal (ARV prophylaxis regimens, maternal age, 
maternal weight, maternal haemoglobin levels, 
maternal CD4 counts, maternal age starting ART, 
duration between enrolment and ART initiation, 
duration between enrolment and date of delivery, 
maternal age at delivery, mode of delivery, place of 
delivery, maternal TB status and other maternal 
medical conditions) and infant (feeding options, babys’ 
NVP prophylaxis.  The key outcome variables were 
Babys’ HIV status at 6 weeks, 9 to <18 months, 18-24 
months) variables were collected.   
2.6 Data analysis  
Data collected was analysed using SPSS (Statistical 
Package for Social Sciences version 20).  Descriptive 
statistics such as mean, median, standard deviation and 
range were used for continuous variables, whereas 
frequencies were used for categorical variables.  The 
Chi-square tests were used to determine any 
associations between baby’s HIV status at 6 weeks, 9 to 
<18 months and 18-24 months and categorical 
variables.  Logistic regression was used to assess the 
association between maternal and infant characteristics 
and baby’s HIV status at 6 weeks, 9 to < 18 months and 
18-24 months. p≤0.05 were considered statistically 
significant. 
2.7 Ethical considerations  
This protocol was reviewed and approved by the 
Kenyatta National Hospital/University of Nairobi Ethics 
and Research Committee (P66/11/2012).  
Confidentiality was assured throughout the study.  
3.  Results and Discussion 
The MOH registers, patient files depicted missing 
information in varying degrees with variables such as 
haemoglobin levels, place of delivery, and mode of 
delivery having over 50% missing data while HIV status 
at 18 months was the best recorded at 1.5% missing 
data. 
ARV prophylaxis regimen provided to HIV-positive 
pregnant women to reduce MTCT rates 
Overall, most mothers 78.1% (n=1367) received 
HAART, 14.2% (n=249) received AZT, 1.7% (n=29) 
received NVP, 4.3% (n=76) received no prophylaxis and 
1.7% (n=30) had not stated whether they received ARV 
prophylaxis or not (Figure 1).  This demonstrated that 
HAART was the main ARV prophylaxis regimen in use 
and AZT and NVP are less commonly administered 
during the study period.  The proportions of ARV 
prophylaxis regimens received across the counties were 
comparable (p=0.466).  
 
Figure 1: ARV prophylaxis regimens received disaggregated by county from January 2012 to June 2013  
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Table 1: HIV transmission rates at 6 weeks, 9 to <18 months and 18-24 months stratified by county, Jan 2012 to June 
2013 
 HIV status at 6 weeks 
(p=0.961) 
 
HIV status at 9 to <18 months 
(p=0.794) 
 
HIV status at 18-24 months 
(p=0.900) 
County  HIV-
negative 
(n,%) 
HIV-
positive 
(n,%) 
Not 
stated 
(n,%) 
 
HIV-
negative 
(n,%) 
HIV-
positive 
(n,%) 
Not 
stated 
(n,%) 
 
HIV-
negative 
(n,%) 
HIV-
positive 
(n,%) 
Not 
stated 
(n,%) 
Bungoma 
(N=408) 
375 
(91.9%) 
23 
(5.6%) 
10 
(2.5%) 
 
374 
(91.7%) 
28 
(6.9%) 
6 
(1.5%) 
 
383 
(93.9%) 
25 
(6.1%) 
- 
Busia 
(N=817) 
760 
(93.0%) 
42 
(5.1%) 
15 
(1.8%) 
 
750 
(91.8%) 
55 
(6.7%) 
12 
(1.5%) 
 
775 
(94.9%) 
42 
(5.1%) 
- 
Kakamega 
(N=394) 
363 
(92.1%) 
24 
(6.1%) 
7 
(1.8%) 
 
351 
(89.1%) 
35 
(8.9%) 
8 
(2.0%) 
 
371 
(94.2%) 
23 
(5.8%) 
- 
Vihiga 
(N=106) 
97 
(91.5%) 
6 (5.7%) 
3 
(2.8%) 
 
96 
(90.6%) 
9 (8.5%) 
1 
(0.9%) 
 
100 
(94.3%) 
6 (5.7%) - 
Total 
(N=1725) 
1595 
(92.5%) 
95 
(5.5%) 
35 
(2.0%) 
 
1571 
(91.1%) 
127 
(7.4%) 
27 
(1.6%) 
 
1625 
(94.4%) 
96 
(5.6%) 
- 
The HIV-negative and HIV-positive babies’ were expressed as (n, %), i.e. absolute count (Frequency, n) and proportion (Percent, %).  
The statistical significance was determined using the Chi-square tests. 
MTCT rates at 6 weeks, 9 to <18 months and 18-24 
months and associated correlates 
The study revealed the HIV transmission rates at 6 
weeks (5.5%, 95% CI: 4.41%-6.59%), 9 to <18 months 
(7.4%, 95%CI: 6.15%-8.65%) and 18-24 months (5.6%, 
95% CI: 4.51-6.69%).  Furthermore, the HIV 
transmission rates at 6 weeks (p=0.961), 9 to <18 
months (p=0.794) and 18-24 months (p=0.900) were 
comparable across counties (Table 1). 
Statistical associations between various correlates for 
MTCT rates abstracted from MoH registers such as 
hemoglobin levels, WHO staging, CD4 cell counts, 
duration between enrollment and ART initiation, type of 
prophylaxis, NVP prophylaxis for the baby received, TB 
status, duration between enrolment and delivery, place 
of delivery, mode of delivery, feeding options at 6 
weeks, feeding options at 9 to <18 months and feeding 
options at 18-24 months and Mother-to-child HIV 
transmission rates at 6 weeks, 9 to <18 months and 18-
24 months were analyzed as shown in Table 2 and 
Annex 1 (Supplementary Information).  
With regard to CD4 count, women with CD4 counts 
greater than 500 cells/mm3 had the lowest HIV 
transmission rate at 18-24 months (3.7%), followed by 
those with CD4 counts between 350 to 500cells/mm3 
(6.3%) while the ones with CD4 counts <350cells/mm3 
had the highest HIV transmission rates (7.3%) (Table 
2).  As such, higher CD4 cell counts amongst women 
were associated with low HIV transmission rates at 6 
weeks (p=0.016), 9 to <18 months (p<0.0001) and 18-
24 months (p=0.029).   
The HIV transmission rate at 6 weeks, 9 to <18 months 
and 18-24 months varied with the type of ARV 
prophylaxis (Table 2) with AZT (3.0%) and HAART 
(5.4%) depicting the lowest HIV transmission rate at 6 
weeks. Use of NVP was associated with highest HIV 
transmission rate of 7.1%.  There were significant 
differences in transmission across the different ARV 
prophylaxes at 6 weeks (p=0.041).  
Further analyses revealed that majority of babies 
received NVP prophylaxis, which was in turn associated 
with lower HIV transmission rates a 6 weeks (p=0.036), 
9 to <18 months (p=0.061) and 18-24 months 
(p=0.330).   
Women on TB treatment had the highest HIV 
transmission rates while those without had the least 
HIV transmission rates at 9 to <18 months (p=0.016) 
and 18-24 months (p=0.009).  However, the HIV 
transmission rates were comparable at 6 weeks 
(p=0.334) between the two groups (Table 2).  These 
observations imply that women having TB were likely 
to transmit HIV to their babies at 9 to <18 months and 
18-24 months period. 
Table 2 further shows the duration between enrolment 
and date of delivery and their effect on MTCT rates.  
Women who delivered within 6 months of enrolment 
had a lower HIV transmission rates at 6 weeks 
(p=0.001), 9 to <18 months (p<0.0001) and 18-24 
months (p=0.001) as compared to those who delivered 
after 6 months.  
Baby’s’ feeding options at 6 weeks, 9 to <18 months and 
18-24 months and the MTCT rates were further 
determined.  Exclusive breastfeeding options were 
associated with MTCT rates of 3.8% (6 weeks), 6.0% (9 
to <18 months) and 3.8% (18-24 months).  The feeding 
options was associated with the MTCT rates at 6 weeks 
(p<0.0001), 9 to <18 months (p=0.001), and 18-24 
months (p<0.0001) (Table 2).  These findings 
demonstrated that feeding options at 6 weeks is a 
strong predictor of MTCT rates at the selected time 
periods. 
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Table 2: Statistical associations between the covariates and baby’s’ HIV Status at 6 weeks, 9 to <18 months and 18-24 months 
 6 weeks  9 to <18 months  18-24 months 
Independent 
variables 
HIV-negative 
(n, %) 
HIV-
positive 
(n,%) 
χ2 p-value 
 
HIV-negative 
(n, %) 
HIV-
positive 
(n,%) 
χ2 p-value 
 
HIV-negative 
(n, %) 
HIV-
positive 
(n,%) 
χ2 p-value 
CD4 count cells 8.321 0.016    19.131 <0.0001    7.094 0.029 
<350 cells 431 (92.7%) 34 (7.3%)  418 (89.1%) 51 (10.9%)  443 (92.7%) 35 (7.3%) 
350 to 500 
cells 
295 (93.7%) 20 (6.3%) 
 
292 (93.6%) 20 (6.4%) 
 
299 (94.3%) 18 (5.7%) 
>500cells 731 (96.3%) 28 (3.7%)  732 (95.6%) 34 (4.4%)  743 (96.1%) 30 (3.9%) 
Not stated 138 (91.4%) 13 (8.6%)  129 (85.4%) 22 (14.6%)  144 (91.7%) 13 (8.3%) 
Type of prophylaxis received 8.273 0.041    7.601 0.055    3.425 0.331 
NVP 26 (92.9%) 2 (7.1%)  23 (85.2%) 4 (14.8%)  26 (92.9%) 2 (7.1%) 
AZT 226 (97.0%) 7 (3.0%)  212 (90.2%) 23 (9.8%)  235 (96.7%) 8 (3.3%) 
HAART 1271 (94.6%) 72 (5.4%)  1262 (93.5%) 88 (6.5%)  1283 (94.6%) 73 (5.4%) 
None 60 (88.2%) 8 (11.8%)  60 (88.2%) 8 (11.8%)  67 (91.8%) 6 (8.2%) 
Not stated 12 (66.7%) 6 (33.3%)  14 (77.8%) 4 (22.2%)  18 (72.0%) 7 (28.0%) 
TB status of the patient 2.193 0.334    8.282 0.016    9.428 0.009 
No signs 1429 (94.7%) 80 (5.3%)  1411 (93.0%) 107 (7.0%)  1457 (94.8%) 80 (5.2%) 
TB signs 61 (93.8%) 4 (6.2%)  61 (93.8%) 4 (6.2%)  61 (93.8%) 4 (6.2%) 
TB Treatment 4 (80%) 1 (20.0%)  3 (60.0%) 2 (40.0%)  4 (66.7%) 2 (33.3%) 
Not stated 101(91.0%) 10 (9.0%)  96 (87.3%) 14 (12.7%)  107 (91.5%) 10 (8.5%) 
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 6 weeks  9 to <18 months  18-24 months 
Independent 
variables 
HIV-negative 
(n, %) 
HIV-
positive 
(n,%) 
χ2 p-value 
 
HIV-negative 
(n, %) 
HIV-
positive 
(n,%) 
χ2 p-value 
 
HIV-negative 
(n, %) 
HIV-
positive 
(n,%) 
χ2 p-value 
Duration between enrolment and delivery 14.002 0.001    18.818 <0.0001    14.622 0.001 
<6months 1153 (96.0%) 48 (4.0%)  1135 (94.5%) 66 (5.5%)  1161 (96.1%) 47 (3.9%) 
6-24months 245 (90.7%) 25 (9.3%)  244 (88.7%) 31 (11.3%)  257 (90.8%) 26 (9.2%) 
24months 82 (92.1%) 7 (7.9%)  80 (86.0%) 13 (14.0%)  87 (92.6%) 7 (7.4%) 
Not stated 115 (88.5%) 15 (11.5%)  112 (86.8%) 17 (13.2%)  124 (88.6%) 16 (11.4%) 
Place of delivery 0.881 0.348    0.718 0.397    0.641 0.423 
Feeding options at 6 weeks 34.748 <0.0001    13.983 0.001    31.520 <0.0001 
EBF 1337 (96.2%) 53 (3.8%)  1305 (94.0%) 83 (6.0%)  1348 (96.2%) 53 (3.8%) 
ERF 16 (84.2%) 3 (15.8%)  16 (84.2%) 3 (15.8%)  16 (84.2%) 3 (15.8%) 
MF 129 (86.0%) 21 (14.0%)  130 (86.7%) 20 (13.3%)  131 (86.8%) 20 (13.2%) 
Not stated  113 (86.3%) 18 (13.7%)  120 (85.1%) 21 (14.9%)  134 (87.0%) 20 (13.0%) 
The number (n) and proportion (%) of HIV-negative and HIV-positive status at 6 weeks, 9 to <18 months and 18-24 months for different variables are shown.  ‘Not 
stated’ = there was no documentation in the Ministry of Health registers.  Statistical analysis was determined by χ2 statistics and the p-value are also shown for each 
variable.  
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Table 3: Logistic regression showing the associations between the covariates and baby’s’ HIV Status at 6 weeks, 9 to <18 months and 18-24 months 
 6 weeks  9 to <18 months  18-24 months 
Independent 
variables 
Odds Ratio 95% CI for OR p-value  Odds Ratio 95% CI for OR p-value  Odds Ratio 95% CI for OR p-value 
CD4 count cells 
<350 cells Ref    Ref    Ref   
350 to 500 cells 2.059 1.232 - 3.444 0.006  2.627 1.674 - 4.121 <0.0001  1.957 1.185 - 3.231 0.009 
>500cells 1.770 0.982 - 3.192 0.058  1.475 0.835 - 2.604 0.181  1.491 0.819 - 2.716 0.192 
Type of prophylaxis received 
NVP 0.577 0.115 - 2.905 0.505  1.304 0.358 - 4.752 0.687  0.859 0.163 - 4.532 0.858 
AZT 0.232 0.081 - 0.666 0.007  0.814 0.346 - 1.911 0.636  0.380 0.127 - 1.134 0.083 
HAART 0.425 0.196 - 0.922 0.030  0.523 0.242 - 1.128 0.098  0.635 0.267 - 1.513 0.306 
None Ref    Ref    Ref   
TB status of the patient 
No signs Ref    Ref    Ref   
TB signs 0.224 0.025 - 2.027 0.183  0.114 0.019 - 0.688 0.018  0.110 0.020 - 0.609 0.011 
TB Treatment 0.262 0.023 - 2.931 0.277  0.098 0.013 - 0.768 0.027  0.131 0.018 - 0.946 0.044 
Duration between enrolment and delivery 
<6months Ref    Ref    Ref   
6-24months 0.488 0.214 - 1.112 0.088  0.358 0.189 - 0.676 0.002  0.503 0.221 - 1.146 0.102 
24months 1.195 0.498 - 2.866 0.689  0.782 0.390 - 1.567 0.488  1.257 0.527 - 2.999 0.606 
Feeding options at 6 weeks 
EBF Ref    Ref    Ref   
ERF 0.244 0.142 - 0.416 <0.0001  0.413 0.246 - 0.696 0.001  0.258 0.149 - 0.444 <0.0001 
MF 1.152 0.309 - 4.297 0.833  1.219 0.326 - 4.562 0.769  1.228 0.328 - 4.597 0.760 
 Omondi et al, Afr. J. Pharmacol. Ther. 2016. 5(1): 42-54 
 
 
A KeSoBAP Publication ©2016. All rights reserved.  ISSN 2303-9841 
49 
 6 weeks  9 to <18 months  18-24 months 
Independent 
variables 
Odds Ratio 95% CI for OR p-value  Odds Ratio 95% CI for OR p-value  Odds Ratio 95% CI for OR p-value 
Feeding options at 9 months 
MF     Ref    Ref   
NBF - -   1.166 0.734 - 1.853 0.514  1.997 1.040 - 3.834 0.038 
RF - -   0.000 - 0.999  0.000 - 0.999 
The significance value, Odds Ratio and 95% confidence intervals are also shown for independent variable taking certain reference categories for each variable. Home delivery for place 
of delivery, C-section for mode of delivery, Yes for baby NVP prophylaxis, WHO stage I for WHO staging, No TB signs for TB status, None for type of prophylaxis, EBF for feeding options 
at 6 weeks, MF for feeding options at 9 months and 18 months were considered as reference groups. Ref=Reference group. 
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The associations between the correlates for MTCT rates 
such as hemoglobin levels, WHO stage, duration 
between enrollment and ART initiation, mode of 
delivery, place of delivery, feeding options at 9 to <18 
months and feeding options at 18-24 months and MTCT 
rates at 6 weeks, 9 to <18 months and 18-24 months 
were determined and were comparable across groups 
(Annex 1, Supplementary Information). 
Additional logistic regression analyses were carried out 
to determine the association between the correlates and 
MTCT rates (Table 3 and Annex 2, Supplementary 
Information).  
Relative to women with CD4 cells count less than 350 
cells/mm3, women with CD4 cells between 350 to 500 
cells/mm3 were about twice likely to have HIV-negative 
babies as opposed to those at 6 weeks (OR=2.059, 95% 
CI=1.232-3.444, p=0.006), 9 to <18 months (OR=2.627, 
95% CI=1.674-4.121, p<0.0001) and 18-24 months 
(OR=1.957, 95% CI=1.185-3.231, p=0.009).  However, 
the likelihood of having HIV-negative babies was 
comparable between those women with CD4 cells count 
greater than 500 cells/mm3 and those with CD4 count 
less than 350 cells/mm3 (Table 3).  
Women with suspected TB signs and symptoms are less 
likely to have HIV-negative babies compared to those 
women who have no TB signs and symptoms at 9 to <18 
months (OR=0.114, 95% CI=0.019-0.688, p=0.018) and 
18-24 months (OR=0.110, 95% CI=0.020-0.609, 
p=0.011).  In addition, women on TB treatment are less 
likely to have HIV-negative babies compared to those 
women who have no TB signs and symptoms at 9 to <18 
months (OR=0.098, 95% CI=0.013-0.768, p=0.027) and 
18-24 months (OR=0.131, 95% CI=0.018-0.946, 
p=0.044).  These differences were statistically 
significant at these selected time points (Table 3).   
Exclusive breastfeeding was associated with lower 
MTCT rates at 6 weeks (OR=0.244, 95% CI=0.142-0.416, 
p<0.0001), 9 to <18 months (OR=0.413, 95% CI= 0.246-
0.696, p=0.001) and 18-24 months (OR=0.258, 95% 
CI=0.149-0.444, p<0.0001).  Babies who are receiving 
exclusive replacement feeds at 6 weeks are less likely to 
be HIV-negative at 18-24 months as compared to babies 
are exclusively breastfed by 71% (p< 0.001) (Table 3).  
The association between WHO stage, duration between 
enrollment and ART initiation, NVP prophylaxis for the 
baby received, of delivery, place of delivery, feeding 
options at 9 to <18 months and at 18-24 months 9 to 
<18 months and MTCT rates across the different times 
were comparable (p>0.05; Annex 2, Supplementary 
Information). 
4. Discussion 
PMTCT Guidelines in Kenya: 2012 - 2013 
In 2012, Kenya published revised PMTCT guidelines 
based on WHO guidelines (2010) (MOH, 2012) which 
we used in the study area with a much greater focus on 
pharmaceutical prophylaxis than previous guidelines 
and which promote earlier initiation of therapy for all 
pregnant women.  Women who are eligible to receive 
ART (CD4 cell count of 350 or below with WHO clinical 
stage of I or II, or WHO clinical stage III or IV, regardless 
of CD4 cell count) were to be started on highly active 
antiretroviral therapy (HAART) regardless of 
gestational age. Women not eligible for HAART would 
be started on combination antiretroviral (ARV) 
prophylaxis at 14 weeks or shortly thereafter and 
receive a combination of AZT, 3TC and NVP at the onset 
of labour (Option B).  The Kenyan guidelines also 
include Option A (single dose nevirapine in labour) 
although option B was encouraged in settings with the 
capacity to monitor women receiving triple therapy 
(MOH, 2012).  This could also be continued through the 
woman’s life without interruption, known as option B-
PLUS. According to the guidelines, at the first ANC visit, 
all HIV infected pregnant women should be given single 
dose nevirapine for themselves (to be taken at the onset 
of labour) and for the infants “to be administered soon 
after birth” (MOH, 2012).    
ARV prophylaxis regimen provided to HIV-positive 
pregnant women to reduce MTCT rates 
The current study revealed that 94% of mothers 
received some form of maternal prophylaxis with 
78.1% receiving HAART, 14.2% receiving AZT and 1.7% 
receiving NVP.  Only 4.3% received no form of ARV 
prophylaxis while 1.7% had not stated whether they 
received ARV prophylaxis or not.  This contrasts with a 
cross-sectional study done in 2010 in South Africa that 
revealed that of all HIV-positive mothers, 30.5% 
received cART and 52.6% received AZT although 83.1% 
received some maternal ARV (Woldesenbet et al, 2015).  
Similarly an assessment done in KwaZulu-Natal, South 
Africa in 2008-2009, revealed that only 13.7% of HIV-
positive pregnant women had started on maternal 
lifelong antiretroviral treatment and 67.2% had 
received maternal zidovudine and nevirapine meaning 
about 81% received some form of maternal ARV 
prophylaxis (Horwood et al, 2012).  These variations in 
ARV regimens in use reflect the changing PMTCT 
guidelines as a result of new WHO guidance as WHO has 
been advocating for more efficacious regimens over the 
years.  The study revealed a near universal uptake of 
ARV prophylaxis of 94% and this contrasts with the 
second Kenya AIDS Indicator Survey that was a 
nationally representative 2-stage cluster sample of 
households that showed 72.3% of HIV-positive 
pregnant women received antepartum antiretroviral 
prophylaxis (Sirengo et al, 2014).  However, it closely 
mirrors a community-based cross-sectional study of 
PMTCT in Nyanza Province, Kenya done in 2011 that 
revealed that 82% were on PMTCT ARVs (Kohler et al, 
2014).  Increasing capacity building of Ministry of 
Health, increased donor support and changes in policy 
environment could be responsible for the increasing 
number of maternal ARVs being provided to HIV-
positive pregnant women in Western Kenya. 
MTCT rates at 6 weeks, 9 to <18 months and 18-24 
months and associated correlates in Western Kenya 
Most countries are making remarkable progress 
towards preventing mother-to-child transmission 
(PMTCT) of HIV, particularly in sub-Saharan Africa. But 
Mother-to-child transmission (MTCT) of HIV continues 
to occur in children during pregnancy, labour and 
delivery, or breastfeeding, at a time, when there are 
available effective interventions to curb the infection 
and better resourced countries have been able to bring 
the risk of children infected though MTCT to less than 
2%.  In sub-Saharan Africa, MTCT rates as high as 25% 
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have been reported (Jackson et al, 2003).  Over 90% of 
HIV infections among children occur through mother-
to-child transmission (UNICEF/UNAIDS/WHO, 2008).  
In the absence of any intervention, rates of MTCT of HIV 
can vary from 15% to 30%, without breastfeeding, and 
can reach as high as 30% to 45% with prolonged 
breastfeeding (De Cock et al, 2000). 
The current study showed that HIV transmission rate at 
18-24 months varied by ARV prophylaxis regimen 
received with AZT showing the lowest HIV transmission 
rate, followed by HAART and NVP at 3.3%, 5.4% and 
7.1%, respectively.  Mothers and their babies who never 
received any form of prophylaxis had 8.2% HIV 
transmission rates.  This contrasts with HIVNET 012 
study that showed an estimated risks of HIV-1 
transmission in the Zidovudine and Nevirapine groups 
to be 25.8% and 15.7% by age 18 months, respectively 
(Jackson et al, 2003).  It further contrasts with Kesho 
Bora study that revealed the cumulative rate of HIV 
transmission at 6 weeks was 3.3% in the triple 
antiretroviral group compared with 5.0% in the 
Zidovudine and single-dose nevirapine group (de 
Vincenzi, 2011).  Study done in Nairobi, Kenya to 
evaluate the effectiveness of the HAART in PMTCT 
demonstrated that up to 90% of children were 
confirmed to be HIV-negative (Ngemu et al, 2014).  
However, other aspects of HAART such as adherence, 
costs, mothers’ behavior during HAART may affect the 
overall efficacy of HAART in PMTCT.  It also contrasts 
with a cohort study in the United States, which showed 
that the risk of MTCT was 10.4% among women 
receiving AZT monotherapy, 1.2% in women receiving 
triple-ARV regimens but is in agreement with 3.8% 
among those receiving dual ARV regimens and (Cooper 
et al, 2002).  In Lusaka, the proportion of HIV PCR-
positive samples was 12% (Sutcliffe et al, 2014).  This, 
however, closely compares with the Kisumu 
Breastfeeding study in Kenya that showed HIV 
transmission rates at 6 weeks and 24 months were 
4.2% and 7%, respectively (Thomas et al, 2011).  The 
current study showed that the HIV transmission rate 
from Mother-to-child at 6 weeks and 18-24 months are 
similar at about 5.5% and 5.6%, respectively and this is 
in tandem with study done in Western Kenya that 
strongly suggested benefit of antiretroviral prophylaxis 
in reducing infant HIV infection but do not show a 
benefit at 18-months when compared to 6 weeks 
transmission rate (Nyandiko et al, 2010).  Few studies 
have compared the programmatic effectiveness of the 
recommended strategies of ante-natal HAART and AZT 
for PMTCT.  A study carried out in Botswana 
demonstrated that maternal HAART was associated 
with a substantial decrease in the rate of mother-to-
child transmission as compared to Zidovudine in a 
programmatic setting (Dryden-Peterson et al, 2011).  
Further studies are needed to understand other 
limitations to the use of HAART in PMTCT of HIV in real 
life situations that could further explain why the MTCT 
rate for AZT seems to be lower than HAART in our study 
area.  The focus for the PMTCT programming should be 
the quality of PMTCT services offered to realize the 
eMTCT targets by 2015 and beyond. 
The CD4 counts is taken as a measure of the level of 
immunity and the lower the CD4 count the higher the 
immunosuppression and vice versa.  According to the 
WHO guidelines, CD4 above 500cells/mm3 is 
considered normal while CD4 between 350cells/mm3 to 
500cells/mm3 is moderate immunosuppression and 
below 350cells/mm3 is mild to severe 
immunosuppression.  The current study revealed that 
lower CD4 cell count was associated with higher HIV 
transmission rate at 6 weeks, 9 to <18 months and 18-
24 months.  This study also found out that women with 
CD4 cells between 350 to 500 cells/mm3 are about 
twice likely to have HIV-negative babies as opposed to 
those women with CD4 cells count less than 
350cells/mm3 (p=0.009).  This corroborates with an 
intervention cohort study that depicted MTCT risk was 
significantly associated with maternal CD4-cell counts 
below 200 cells per mL (Bryson, 1996; Coovadia et al, 
2007; Landesman et al, 1996).  Therefore, early ANC 
attendance and HIV testing for women in reproductive 
age group should be strongly promoted. 
In HIV-infected women, co-infections that target the 
placenta, genital tract have been shown to increase the 
risk for MTCT.  Active co-infection stimulates the 
release of cytokines and inflammatory agents that 
enhance HIV replication and this weakens natural 
defenses to MTCT.  Tuberculosis (TB) is a major cause 
of disease morbidity and mortality more so amongst 
HIV infected individuals.  For women, the greatest 
burden of TB occurs during the reproductive years 
(ages 15-49 years).  In this study, women with 
suspected TB signs and symptoms and on TB treatment 
are less likely to have HIV-negative babies compared to 
those women who have no TB signs and symptoms at 9 
to <18 months and 18-24 months.  Active TB infection is 
normally associated with lower CD counts amongst HIV 
infected individuals. Active TB infection increases HIV 
load and is associated with immunosuppression, which 
may explain the association between TB and MTCT (Day 
et al, 2004; Goletti et al, 1996; Pillay et al, 2004; Toossi 
et al, 2001; Zhang et al, 1995). 
In Africa, more than 95% of infants are currently 
breastfed, but feeding practices are often inadequate: 
feeding water, and other liquids, to breastfed infants is a 
widespread practice. Nevertheless, prolonged 
breastfeeding is common, and the median duration of 
breastfeeding ranges between 16 and 28 months.  
Urbanization and mothers' education are the major 
factors that tend to shorten breastfeeding.  However, 
recent trends show an increase in early initiation and in 
duration of breastfeeding as a result of promotion 
efforts deployed by WHO and UNICEF, local 
governments, and non-governmental organizations.  To 
prevent MTCT of HIV, WHO recommends replacement 
feeding where feasible and safe.  Otherwise, mothers 
are encouraged to practice exclusive breastfeeding for 
the first months of life followed by early and rapid 
weaning.  Exclusive breastfeeding for a few months 
could carry a lower risk of death than replacement 
feeding. Infants of all mothers, whether HIV-positive or 
not, will benefit from improving the rate of exclusive 
breastfeeding (Dop, 2002).   
In the current study, babys’ who received exclusive 
breastfeeding at 6 weeks had a significantly low HIV 
transmission rate of 3.9% compared to those who 
received exclusive replacement feeding and mixed 
feeding each at about 15% (p<0.001) and it emerged as 
the strongest predictor of babies’ HIV status at 18-24 
months.  This contrasts with an intervention cohort 
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study done in 2007 that showed 14.1% of exclusively 
breastfed infants were infected with HIV-1 by age of 6 
weeks (Coovadia et al, 2007).  It also contrasted with a 
cohort study done in Durban, South Africa in 1997 that 
found out that HIV transmission rate was 39% in those 
exclusively breastfed, 24% in those fed exclusively on 
formula and 32% in those receiving mixed feeding and 
that 50% of HIV-infected infants exclusively breastfed 
(Bobat et al, 1997).  Similarly study done in KwaZulu 
Natal, South Africa revealed 14.1% of exclusively 
breastfed infants were infected with HIV-1 by age 6 
weeks and 19.5% by 6 months (Coovadia et al, 2007). 
Babies who are receiving exclusive replacement feeds at 
6 weeks are less likely to be HIV-negative at 18-24 
months as compared to babies that are exclusively 
breastfed by approximately 74% (p< 0.001).  The first 
study to show such an association came from south 
Africa and found that infants who received both breast 
milk and other feeds were significantly more likely to be 
infected by 15 months of age (36%) than those who had 
been exclusively breastfed for the first three months 
(25%) or formula fed (19%) (Iliff et al, 2005).  The 
study findings also compares favorably with a 
prospective cohort study done in Durban, South Africa 
that showed exclusive breastfeeding carried a 
significantly lower risk of HIV-1 transmission than 
mixed feeding (Coutsoudis et al, 1999).  In addition, 
exclusive breastfeeding has been found to result in a 
three-to four-fold decrease in HIV transmission 
compared to non-exclusive breastfeeding in several 
large prospective studies South Africa (Coovadia et al, 
2007; Coutsoudis et al, 2001), Zimbabwe (Iliff et al, 
2005) and Ivory Coast (Becquet et al, 2008).  Similarly, 
studies have shown that breastfed infants who also 
received solids ere significantly more likely to acquire 
infection than were exclusively breastfed children 
(p=0.018) (Coutsoudis et al, 2001).  In Ethiopia, mixed 
infant feeding had been shown to increase the risk of 
mother- to- child transmission of HIV (Zelalem Berhan 
et al, 2014).  Therefore this study corroborates earlier 
findings that have demonstrated exclusive 
breastfeeding within the first 6 months do reduce the 
risk of HIV transmission from Mother-to-child.  
Exclusive breastfeeding offers HIV-1-infected women in 
developing countries an affordable, culturally 
acceptable, and effective means of reducing mother-to-
child transmission of HIV-1 while maintaining the 
overwhelming benefits of breastfeeding.  Advocacy and 
campaigns for EBF needs to be sustained at all levels to 
ensure 100% uptake and coverage.  
The study found out that for every one year duration 
between enrollment and delivery, the chances of the 
baby having an HIV-negative status at 18-24 months 
was approximately 1.5 times (p=0.001).  This is in 
tandem with study that showed that starting ARV 
prophylaxis earlier in pregnancy is more effective to 
reduce infant HIV (Gaillard et al, 2004).  Similarly, 
shorter duration of HIV treatment was associated with 
increased risk of mother-to-child transmission of HIV 
(Zelalem Berhan et al, 2014).  So women should be 
encouraged to plan pregnancies and attend antenatal 
care sufficiently early, to diagnose and assess maternal 
HIV infection and be started on ARVs.  Therefore, early 
ANC attendance and HIV testing of women and girls in 
the reproductive age should be encouraged and 
promoted by all stakeholders.  
The greatest strength of this study is that it was 
conducted in the real world setting of Ministry of Health 
facilities in the four counties in Western Kenya.  As a 
result, the findings of our study are more likely to 
reflect actual outcomes of MTCT rates within the public 
health facilities in Kenya and sub-Saharan African than 
do results from randomized clinical trials. 
5. Conclusion 
The results of this study are in agreement with some 
previous studies.  The study reported MTCT rate varied 
at selected time points.  Notable differences were 
reported with regard to the ARV prophylaxis regimen 
with dual therapy (AZT) recording the lowest MTCT 
rate at 18-24 months. Majority of the mother-baby pairs 
received HAART prophylaxis, followed by AZT.  Very 
few were given NVP prophylaxis and fewer were not 
given any form of ARV prophylaxis.  In the study, the 
HIV status at 18-24 months also showed variation with 
the feeding options.  However, feeding option at 6 
weeks was a key predictor of HIV status at 18-24 
months.  EBF had a low HIV positivity as compared with 
ERF and MF that had much higher HIV positivity.  The 
study also found out that most babies with HIV-negative 
status at 18-24 months were EBF at 6 weeks as opposed 
to those who are HIV-positive status.  Early treatment 
initiation was associated with HIV-negative status at 18-
24 months. 
 
Conflict of Interest Declaration 
The authors declare no conflict of interest.  
 Acknowledgements 
The authors are grateful to the Vihiga, Bungoma, Busia 
and Kakamega County Health Directors, the health care 
workers at the health facilities and staff at Alupe KEMRI 
Laboratory for their cooperation and support.  The 
authors are indebted to the MCH/PMTCT in-charges at 
the health facilities in the four counties who took part in 
the study.  Specially acknowledge is reserved for Jude 
Mutoro, the lead research assistant for excellent 
supervision of the data collection and logistical support.   
References 
Becquet R, Ekouevi DK, Menan H, Amani-Bosse C, Bequet L, 
Viho I, Dabis F, Timite-Konan M and Leroy V (2008) Early 
mixed feeding and breastfeeding beyond 6 months increase 
the risk of postnatal HIV transmission: ANRS 1201/1202 
Ditrame Plus, Abidjan, Cote d'Ivoire. Prev. Med. 47:27-33. 
Bobat R, Moodley D, Coutsoudis A and Coovadia H (1997) 
Breastfeeding by HIV-1-infected women and outcome in their 
infants: a cohort study from Durban, South Africa. AIDS 
11:1627-1633. 
Bryson YJ (1996) International Conference on AIDS No11, 
Vancouver Canada.  Volume 10: pp. S33-S42. . 
Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, 
Hayani K, Handelsman E, Smeriglio V, Hoff R and Blattner W 
(2002) Combination antiretroviral strategies for the 
treatment of pregnant HIV-1-infected women and prevention 
 Omondi et al, Afr. J. Pharmacol. Ther. 2016. 5(1): 42-54 
 
 
A KeSoBAP Publication ©2016. All rights reserved.  ISSN 2303-9841 
53 
of perinatal HIV-1 transmission. J. Acquir. Immune. Defic. 
Syndr. 29:484-494. 
Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, 
Bennish ML and Newell ML (2007) Mother-to-child 
transmission of HIV-1 infection during exclusive breastfeeding 
in the first 6 months of life: an intervention cohort study. 
Lancet 369:1107-1116. 
Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY and 
Coovadia HM (2001) Method of feeding and transmission of 
HIV-1 from mothers to children by 15 months of age: 
prospective cohort study from Durban, South Africa. AIDS 
15:379-387. 
Coutsoudis A, Pillay K, Spooner E, Kuhn L and Coovadia HM 
(1999) Influence of infant-feeding patterns on early mother-
to-child transmission of HIV-1 in Durban, South Africa: a 
prospective cohort study. South African Vitamin A Study 
Group. Lancet 354:471-476. 
Day JH, Grant AD, Fielding KL, Morris L, Moloi V, 
Charalambous S, Puren AJ, Chaisson RE, De Cock KM, Hayes RJ 
and Churchyard GJ (2004) Does tuberculosis increase HIV 
load? J. Infect. Dis. 190:1677-1684. 
De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff 
E, Alnwick DJ, Rogers M and Shaffer N (2000) Prevention of 
mother-to-child HIV transmission in resource-poor countries: 
translating research into policy and practice. JAMA 283:1175-
1182. 
de Vincenzi I (2011) Triple antiretroviral compared with 
zidovudine and single-dose nevirapine prophylaxis during 
pregnancy and breastfeeding for prevention of mother-to-
child transmission of HIV-1 (Kesho Bora study): a randomised 
controlled trial. Lancet Infect. Dis. 11:171-180. 
DOC (2001) United Nations General Assembly Special Session 
on HIV/AIDS.  New York, USA, USA. 
Dop MC (2002) [Breastfeeding in Africa: will positive trends 
be challenged by the AIDS epidemic?]. Sante 12:64-72. 
Dryden-Peterson S, Jayeoba O, Hughes MD, Jibril H, 
Keapoletswe K, Tlale J, Modise TA, Asmelash A, Moyo S, van 
Widenfelt E, Makhema J, Essex M, Shapiro RL and Lockman S 
(2011) Highly active antiretroviral therapy versus zidovudine 
for prevention of mother-to-child transmission in a 
programmatic setting, Botswana. J. Acquir. Immune. Defic. 
Syndr. 58:353-357. 
Gaillard P, Fowler MG, Dabis F, Coovadia H, Van Der Horst C, 
Van Rompay K, Ruff A, Taha T, Thomas T, De Vincenzi I and 
Newell ML (2004) Use of antiretroviral drugs to prevent HIV-1 
transmission through breast-feeding: from animal studies to 
randomized clinical trials. J. Acquir. Immune. Defic. Syndr. 
35:178-187. 
Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, 
Klein RS, Munsiff SS, Ortona L, Cauda R and Fauci AS (1996) 
Effect of Mycobacterium tuberculosis on HIV replication. Role 
of immune activation. J. Immunol. 157:1271-1278. 
Horwood C, Vermaak K, Butler L, Haskins L, Phakathi S and 
Rollins N (2012) Elimination of paediatric HIV in KwaZulu-
Natal, South Africa: large-scale assessment of interventions for 
the prevention of mother-to-child transmission. Bull. World 
Health Organ. 90:168-175. 
Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, 
Nathoo KJ, Moulton LH, Ward BJ and Humphrey JH (2005) 
Early exclusive breastfeeding reduces the risk of postnatal 
HIV-1 transmission and increases HIV-free survival. AIDS 
19:699-708. 
Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, 
Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, 
Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, 
Mofenson L, Miotti P, Gigliotti M, Bray D and Mmiro F (2003) 
Intrapartum and neonatal single-dose Nevirapine compared 
with Zidovudine for prevention of mother-to child 
transmission of HIV-1 in Kampala, Uganda: 18-month follow-
up of the HIVNET 12 randomized trial. Lancet 362:859-868. 
Kohler PK, Okanda J, Kinuthia J, Mills LA, Olilo G, Odhiambo F, 
Laserson KF, Zierler B, Voss J and John-Stewart G (2014) 
Community-based evaluation of PMTCT uptake in Nyanza 
Province, Kenya. PLoS One 9:e110110. 
Landesman HS, A. Kalish AL, David N, Burns ND, Minkoff H, 
Fox EH, Zorrilla C, Garcia P, Fowler GM, Mofenson L and 
Tuomala R (1996) The Women and Infants Transmission 
Study. New Engl. J. Med. Volume 334:1617-1623. 
MOH (2004) National Prevention of Mother to Child 
Transmission Strategic Management Plan Year 2003-2007. 
MOH (2005) Kenya National PMTCT guideline. 
MOH (2008) Guidelines for Prevention of Mother to Child 
Transmission (PMTCT) of HIV/AIDS in Kenya.  3rd Edition. 
MOH (2012) Guidelines for PMTCT of HIV/AIDS in Kenya. 
Ngemu EK, Khayeka-Wandabwa C, Kweka EJ, Choge JK, Anino 
E and Oyoo-Okoth E (2014) Effectiveness of option B highly 
active antiretroviral therapy (HAART) prevention of mother-
to-child transmission (PMTCT) in pregnant HIV women. BMC 
Res. Notes. 7:52. 
Nyandiko WM, Otieno-Nyunya B, Musick B, Bucher-
Yiannoutsos S, Akhaabi P, Lane K, Yiannoutsos CT and Wools-
Kaloustian K (2010) Outcomes of HIV-exposed children in 
western Kenya: efficacy of prevention of mother to child 
transmission in a resource-constrained setting. J. Acquir. 
Immune Defic. Syndr. 54:42-50. 
Pillay T, Adhikari M, Coovadia HM, Moodley J, Khan M and 
Sullivan JL (2004) In utero HIV infection in pregnancies 
complicated by tuberculosis in Durban, South Africa. Arch. Dis. 
Child Fetal Neonatal Ed. 89:F468-469. 
Sirengo M, Muthoni L, Kellogg TA, Kim AA, Katana A, 
Mwanyumba S, Kimanga DO, Maina WK, Muraguri N, Elly B 
and Rutherford GW (2014) Mother-to-child transmission of 
HIV in Kenya: results from a nationally representative study. J. 
Acquir. Immune Defic. Syndr. 66 Suppl 1:S66-74. 
Sutcliffe CG, van Dijk JH, Hamangaba F, Mayani F and Moss WJ 
(2014) Turnaround time for early infant HIV diagnosis in 
rural Zambia: a chart review. PLoS One 9:e87028. 
Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, 
Otieno J, Jamieson D, Thigpen MC, Bulterys M, Slutsker L, De 
 Omondi et al, Afr. J. Pharmacol. Ther. 2016. 5(1): 42-54 
 
 
A KeSoBAP Publication ©2016. All rights reserved.  ISSN 2303-9841 
54 
Cock KM, Amornkul PN, Greenberg AE and Fowler MG (2011) 
Triple-antiretroviral prophylaxis to prevent mother-to-child 
HIV transmission through breastfeeding--the Kisumu 
Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 
8:e1001015. 
Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger 
T, Hom DL, Aung H, Mugyenyi P, Ellner JJ and Whalen CW 
(2001) Impact of tuberculosis (TB) on HIV-1 activity in dually 
infected patients. Clin. Exp. Immunol. 123:233-238. 
UNAIDS (2009). 
UNAIDS (2010) Global Report. UNAIDS Report on the Global 
AIDS Epidemic. 
UNAIDS (2014) Progress Report on the Global Plan 2014. 
UNICEF/UNAIDS/WHO (2008) Towards Universal Access: 
Scaling up HIV services for women and children in the health 
sector - Progress Report 2008, UNICEF, New York. 
WHO (2014a) HIV/AIDS. 
WHO (2014b) HIV/AIDS Factsheet, WHO. 
Woldesenbet S, Jackson D, Lombard C, Dinh TH, Puren A, 
Sherman G, Ramokolo V, Doherty T, Mogashoa M, Bhardwaj S, 
Chopra M, Shaffer N, Pillay Y and Goga A (2015) Missed 
Opportunities along the Prevention of Mother-to-Child 
Transmission Services Cascade in South Africa: Uptake, 
Determinants, and Attributable Risk (the SAPMTCTE). PLoS 
One 10:e0132425. 
Zelalem B, Fantu A, Molla G, Mulugeta T, Muluken A and Yilkal 
T (2014) Risk of HIV and associated factors among infants 
born to HIV positive women in Amhara region, Ethiopia: a 
facility based retrospective study. BMC Res. Notes 7: 876. 
Zhang Y, Nakata K, Weiden M and Rom WN (1995) 
Mycobacterium tuberculosis enhances human 
immunodeficiency virus-1 replication by transcriptional 
activation at the long terminal repeat. J. Clin. Invest. 95:2324-
2331
 
